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Background:  We  examine  major  causes  of  death  amongst  persons  in  contact  with  drug-treatment  services
across  Scotland  during  April  1996–March  2006,  hereafter  Scottish  Drug  Misuse  Database  (SDMD)  cohort.
Methods:  Drug-treatment  records  were  linked  to  national  registers  of  deaths  and  hepatitis  C virus  (HCV)
diagnoses.  For  eras  1996/97–2000/01  and  2001/02–2005/06,  we  calculated  cause-speciﬁc  death-rates
and  standardised  mortality  ratios  (SMRs)  using  age-,  sex-  and  calendar-rates  of  the  general  Scottish
population.  Major  causes  of  death  were  identiﬁed  by high  SMRs  (>5  across  eras)  or  rates  (>50  per  100,000
person-years  in  either  era),  and  their  time-speciﬁc  inﬂuences  characterised  by  proportional  hazards
analyses.
Results:  The  SDMD  cohort  comprised  69,456  individuals,  350,315  person-years  and  2590  deaths.  The
overall  SMR  reduced  from  6.4 (95%  CI:  6.0–6.9)  to  4.8  (95%  CI:  4.6–5.0)  between  eras.  We  identiﬁed  ﬁve
major  causes  of  death:  drug-related  (1383  deaths),  homicide  (118)  and  infectious  diseases  (90)  with  high
SMRs;  suicide  (269)  and  digestive  system  disease  (168)  with  high  rates.  HCV  diagnosis  marked  individuals
with  at  least  double  the  risk  of  cause-speciﬁc  mortality,  including  adjusted  hazard  ratio  (HR)  for  no
HCV  diagnosis  of  0.46  (95%  CI: 0.41–0.53)  for  drug-related  deaths  (DRDs)  and  0.15  (95% CI: 0.10–0.22)
for  death  from  digestive  system  disease.  Increased  DRD  risk  at older  age  (>34  years)  appeared  speciﬁc
2to  HCV-diagnosed  individuals  (interaction:  1 = 7.7,  p =  0.01).  Alcohol  misuse  increased  HRs:  for  DRD
(1.76,  95%  CI:  1.50–2.06),  suicide  (1.88,  95%  CI: 1.35–2.60),  deaths  from  digestive  system  disease  (3.19,
95%  CI:  2.21–4.60)  and  non-major  causes  (1.87,  95%  CI:  1.49–2.35).  Stimulant  misuse  increased  suicide
risk:  adjusted  HR  1.91  (95%  CI: 1.43–2.54).
Conclusions: Drug-users  in Scotland  are  exposed  to  variously  increased  mortality  risks.  HCV-diagnosed
ly  vuindividuals  are  particular
ntroduction
Record-linkage enables comprehensive, non-intrusive surveil-
ance of elusive, and potentially vulnerable, sub-populations.
reviously in Scotland, Bird and Hutchinson (2003) used record-
inkage ﬁrst to investigate drug-related and other-cause mortality
f male prisoners in the 12 weeks following release from prison in
996–1999, and subsequently to study the mortality of all individ-
als (and speciﬁcally injecting drug users or IDUs) who had been
iagnosed with Hepatitis C virus (HCV) infection (Bird on behalf of
OSMO Workshop, 2010; McDonald et al., 2009).
Large-scale record-linkage studies of IDUs have also been con-
ucted in New South Wales, Australia: by Amin, Law, Bartlett,
aldor, and Dore (2006) on the mortality of all HCV-diagnosed indi-
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viduals and by Degenhardt et al. (2009) on 42,676 individuals in
opioid replacement treatment (425,998 person-years or pys). In-
opioid-treatment all-cause standardised mortality ratio (SMR) was
4.5 (95% conﬁdence interval (CI): 4.3–4.8) and out-of-treatment
was 8.0 (95% CI: 7.7–8.3); but risk factors for cause-speciﬁc mortal-
ity were not addressed. Bargagli et al. (2006) reported SMRs of 6 or
more for opiate-user cohorts recruited from drug-treatment cen-
tres across eight European study sites during 1990–98. There was,
however, limited covariate information across cohorts on which to
base analyses of risk factors for time to drug-related death (DRD)
(COSMO Workshop, 2010). The mortality of large drug-user cohorts
has therefore been selected as a key theme for 2011 by the Euro-
pean Monitoring Centre from Drugs and Drug Addiction (EMCDDA,
2011).
Open access under CC BY license.There have been several cohort studies on the mortality of
UK drug-users, or drug-treatment recipients (Bloor et al., 2008;
Cornish, MacLeod, Strang, Vickerman, & Hickman, 2010; Frischer,
Goldberg, Rahman, & Berney, 1997; Ghodse, Oyefeso, & Kilpatrick,
 Journ
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998; Gossop, Marsden, & Stewart, 2001; Kimber et al., 2010;
cCowan, Kidd, & Fahey, 2009) but even the more recent studies
ave lacked statistical power or had limited access to cause-speciﬁc
ortality.
The Scottish Drug Misuse Database (SDMD) records all new con-
acts with drug treatment and support services across Scotland and
s, undoubtedly, the most extensive coverage of such an elusive
nd vulnerable sub-population in Scotland. At each SDMD reg-
stration, demographic information and details on reported drug
se behaviours are recorded. By linkage of SDMD registrations
ith mortality records, we have been able to track Scottish drug
reatment clients over time and so we provide a comprehensive
ccount of the cause-speciﬁc mortality rates of all clients regis-
ered between 1 April 1996 and 31st March 2006 (over 2500 deaths,
50,000 pys and nearly 70,000 individuals).
Moreover, in Scotland, approximately half of IDUs are HCV-
nfected (Health Protection Agency Centre for Infections, 2009)
nd 90% of the HCV-diagnosed population has injected drugs
Hutchinson, Bird, & Goldberg, 2005). Additional linkage of SDMD
egistrations with HCV diagnoses has enabled us to characterise
ajor cause-speciﬁc mortality risks by HCV diagnosis, as well as
emographic and drug misuse characteristics.
ethods
tudy population and data sources
By a variation on the Privacy Advisory Committee permissions
or McDonald et al. (2009), linked data were available for studying
DMD clients.
The  SDMD, held by Information Services Division (ISD), records
ll registrations for drug-treatment or support in Scotland. Each
egistration ofﬁcially corresponds to a “new” contact, deﬁned as
 ﬁrst or repeat presentation if at least six months have elapsed
ince last attendance. For each registration, SDMD holds limited
dentifying information: sex, date of birth, forename initial, ﬁrst and
ourth letter of surname, and postcode sector of residence. Data are
lso held on risk behaviours such as illicit drugs used and injector
tatus. SDMD records were available on 69,456 unique individuals
ho attended drug services between 1 April 1996 and 31 March
006.
The General Register Ofﬁce for Scotland (GROS) holds a national
egister of all deaths in Scotland. For each death are recorded: sex,
ge and underlying cause of death (International Classiﬁcation of
iseases Ninth Revision, ICD9, for deaths registered 1989–1999, or
enth Revision thereafter, ICD10). In addition, Health Protection
cotland holds a database on all individuals who have been diag-
osed hepatitis C virus (HCV) antibody positive in Scotland since
991 (Shaw et al., 2003).
To identify deaths and HCV diagnoses in our study cohort, data
rom SDMD clients were linked with the national register of deaths
o 30 September 2006 and the database of HCV diagnoses to 30
une 2006. Record-linkage was carried out by ISD using a proba-
ilistic approach. For each SDMD client in the cohort, potentially
orresponding death and HCV records were ranked according to a
inkage score which was based on a probabilistically weighted com-
ination of the occurring identiﬁers. The top-ranked match would
e successful if the score exceeded a pre-determined threshold
see Appendix A and Merrall, submitted for publication, for further
etails).
The linked dataset was anonymised before transfer to MRC  Bio-
tatistics Unit for analysis. ISD have previously estimated their
rocedure to have an error rate (either false positives or false
egatives) of <5% (Kendrick & Clarke, 1993). We  identiﬁed andal of Drug Policy 23 (2012) 24– 32 25
de-selected  some erroneous linkages, such as deaths before SDMD
contacts, but other low-level inconsistencies inevitably remain.
To  make comparisons with the general Scottish population,
GROS provided mid-year population estimates, by sex and 5-
year age group (0–4, 5–9, . . .,  ≥85 years) from 1996 to 2006; and
numbers of deaths by cause (as described below) for the same
cross-classiﬁcations (GROS, personal communication: Frank Dixon,
3 September 2009).
Deaths  were analysed according to the underlying cause; and
all major “disease-related” and “external” categories were exam-
ined. In addition, we investigated DRDs, as deﬁned by GROS, see
Jackson (2001) and the UK’s Department of Health (2001), which
included: mental and behavioural disorders due to psychoactive
substance misuse (ICD9: 292, 304 excluding 304.6; ICD10: F11–F16,
F19); accidental poisoning (ICD9: E850–E858; ICD10: X40–X44);
intentional self-poisoning by drugs, medicaments and biologi-
cal substances (ICD9: E950.0–E950.5; ICD10: X60–X64); assault
by drugs, medicaments and biological substances (ICD9: E962.0;
ICD10: X85); and events of undetermined intent, poisoning (ICD9:
E980.0–E980.5; ICD10: Y10–Y14). Any ICD codes that corresponded
to DRDs were excluded from other major categories so that all
categories under study are mutually exclusive.
Standardised mortality ratios (SMRs)
Time-at-risk was from the date of an individual’s ﬁrst atten-
dance at drug services after 1 April 1996 until the earlier of date of
death and end-of-study, 1 April 2006. Cause-speciﬁc SMRs were
calculated by comparing the observed to expected number of
deaths. Expected mortality was calculated by applying the age,
sex, year and cause-speciﬁc rates of the general Scottish population
to the respective times-at-risk of the SDMD cohort. We  expected
variability across calendar–time, and so separate calculations were
made for two ﬁve-year eras: 1 April 1996 to 31 March 2001 and 1
April 2001 to 31 March 2006. Conﬁdence intervals for SMRs were
calculated by the exact method of Mulder (1983).
Time-to-event analyses
To  investigate demographic and behavioural risk factors for
drug-related and other speciﬁc causes of death, proportional haz-
ards models with time-dependent covariates were used. Calendar
time was  likely to have the most complex effect on the hazard and
so was  chosen as the baseline time-scale with 1 April 1996 set as
t = 0 for all in the SDMD cohort.
Demographic and misuse covariates were derived from SDMD
records. We  coded separate indicator variables for the misuse of
opiates, sedatives, stimulants, cannabis or tobacco, and alcohol; and
categorised time since most recent registration, with 1–2 years as
the reference category, and indicators for ≤12 weeks, 3–12 months,
2–5 years and >5 years.
All  covariates, except age, were updated according to subse-
quent SDMD registrations. Age was  updated according to calendar
time. Birth-year, but not month and day, was  provided for analy-
sis and so birthdays were chosen at random, assuming them to be
uniformly distributed throughout the year.
Linked HCV diagnosis records identiﬁed if, and when, individu-
als were diagnosed with HCV. In our analyses, HCV diagnoses were
ﬂagged up 30 days after the date of diagnosis, as in McDonald et al.
(2009), to avoid biased associations with cause-speciﬁc mortality
risks that could be due to an increased risk of death at the time of
diagnosis.Prior to speciﬁc investigations of mortality, we assessed Schoen-
feld residuals (Therneau & Grambsch, 2000), to check whether
regression effects were constant over time. For DRDs, the regression
effect associated with regional health board violated the propor-
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Table 1
Characteristics of the study population at ﬁrst observed SDMD registration (baseline): overall and by opiate misuse status at ﬁrst observed SDMD registration; and deaths and follow-up by demographic and misuse characteristics.
Individuals (%) as recorded at baseline unless speciﬁed otherwise Deaths (DRDs) Person-years Death rate per 1000 pys (95% CI)
Whole SDMD cohort Opiate misuse at
baseline
No  opiate misuse
at  baseline
Across study period
Total 69,456 45,377 24,079
Person-years  350,315 239,771 110,544
Deathsa (DRDs) 2590 (1383) 1772 (1046) 818 (337)
No.  of SDMD registrationsa
One episode 41,189 (59) 23,221 (51) 17,968 (75) 1305 (626) 228,968 5.7 (5.4–6.0)
2–5 episodes 24,971 (36) 19,425 (43) 5546 (23) 1210 (717) 113,530 10.7 (10.1–11.3)
6–10 episodes 3177 (5) 2636 (6) 541 (2) 74 (40) 7594 9.7 (7.7–12.2)
>10 episodes 119 (0) 95 (0) 24 (0) 1 (0) 224 4.5 (0.1–24.9)
Age
<25 years 29,568 (43) 19,840 (44) 9728 (40) 527 (341) 89,929 5.9 (5.4–6.4)
25–34 years 28,150 (41) 19,307 (43) 8843 (37) 1085 (665) 175,660 6.2 (5.8–6.6)
>34 years 11,738 (17) 6230 (14) 5508 (23) 978 (377) 84,726 11.5 (10.8–12.3)
Sex
Male 48,084 (69) 31,453 (69) 16,631 (69) 2066 (1110) 243,018 8.5 (8.1–8.9)
Female 21,372 (31) 13,924 (31) 7448 (31) 524 (273) 107,297 4.9 (4.5–5.3)
Injector status
Present injector 22,194 (32) 21,495 (47) 699 (3) 1109 (721) 124,149 8.9 (8.4–9.5)
Past injector 11,010 (16) 6121 (13) 4889 (20) 589 (292) 67,128 8.8 (8.1–9.5)
Never injector 32,239 (46) 16,308 (36) 15,931 (66) 745 (301) 140,931 5.3 (4.9–5.7)
Unavailable 4013 (6) 1453 (3) 2560 (11) 147 (69) 18,107 8.1 (6.9–9.5)
Misuse of – (N.B. multiple categories may  be reported)
Opiates 45,377 (65) 45,377 (100) 0 (0) 1690 (1026) 231,551 7.3 (7.0–7.7)
Sedatives 21,114 (30) 16,783 (37) 4331 (18) 838 (484) 111,213 7.5 (7.0–8.1)
Stimulants 11,255 (16) 4961 (11) 6294 (26) 383 (202) 53,037 7.2 (6.5–8.0)
Cannabis or tobacco 21,866 (31) 12,027 (27) 9839 (41) 632 (340) 103,166 6.1 (5.7–6.6)
Alcohol 7,894 (11) 2847 (6) 5047 (21) 407 (192) 34,385 11.8 (10.7–13.0)
HCV positive diagnosis (30+ day survivors only)
Not diagnoseda 59,977 (86) 37,898 (84) 22,079 (92) 1857 (1014) 309,228 6.0 (5.7–6.3)
Diagnosed 733 (369) 41,087 17.8 (16.6–19.2)
At baseline 3094 (4) 2154 (3) 940 (1)
By  end of study period 9479 (14) 7479 (16) 2000 (8)
Era  of ﬁrst registration
1  April 1996–31 March 2001 36,675 (53) 25,674 (57) 11,001 (46) 2032 (1115) 270,195 7.5 (7.2–7.9)
1  April 2001–31 March 2006 32,781 (47) 19,703 (43) 13,078 (54) 558 (268) 80,120 7.0 (6.4–7.6)
Drug-treatment agency
GP  9165 (13) 5979 (13) 3186 (13) 328 (163) 48,125 6.8 (6.1–7.6)
Specialist drug service 54,638 (79) 34,957 (77) 19,681 (82) 1986 (1037) 269,616 7.4 (7.0–7.7)
Other 5653 (8) 4441 (10) 1212 (5) 276 (183) 32,573 8.5 (7.5–9.5)
Total 69,456 45,377 24,079 2590 (1383) 350,315 7.4 (7.1–7.7)
a By either end of follow-up or death.
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ional hazards assumption. A dramatic decrease in relative DRD risk
as observed for Lothian health board after a string of methadone-
verdose deaths (Greenwood, Zealley, Gorman, Fineron, & Squires,
997), which Weinrich and Stuart (2000) attributed to lesser super-
ision of methadone consumption in Lothian than Glasgow up to
000. To accommodate the observed non-proportionality, an inter-
ction was ﬁtted which allowed the effect associated with Lothian
ealth board to differ across epochs (April 1996–September 2000;
ctober 2000–March 2003; April 2003–March 2006). The ﬁtted
nteraction ensures that our inferences are not confounded by this
ime-speciﬁc, regional variation which is of national interest only.
All statistical analyses were conducted using R version 2.9.0 (R
evelopment Core Team, 2009).
esults
DMD cohort
The  SDMD cohort comprised 69,456 individuals, including
37,510 SDMD episodes and 3094 HCV diagnoses at baseline. Dur-
ng 350,315 pys of follow-up, there were 6385 HCV diagnoses and
590 deaths. Those younger than 25 years at ﬁrst registration made
p 43% (29,568) of the SDMD cohort but contributed only 26%
89,929) of pys of follow-up. Table 1 presents summary character-
stics for the SDMD cohort, and for individuals who did or did not
eport opiate misuse at their baseline registration (45,377, 65%, or
4,079, 35%, respectively). The “non-opiate” clients experienced a
igniﬁcantly lower, but still substantial, DRD rate than the opiate
ndividuals: 305 (95% CI: 272–337) versus 436 (95% CI: 410–463)
RDs per 100,000 pys.
In comparison with the opiate sub-population, a greater propor-
ion of non-opiate clients: presented only once (75% versus 51%);
ere more than 34 years of age (23% versus 14%); were never-
njectors (66% versus 36%); reported misuse of stimulants (26%
ersus 11%), cannabis or tobacco (41% versus 27%) and alcohol (21%
ersus 6%).
By  the end of follow-up, over half (54% = 37,181/69,456) of the
DMD cohort had a recorded history of injection drug use (past
r present) and, of these, 23% (8418/37,181) were diagnosed with
CV. Injectors represented 89% of all HCV diagnoses in the SDMD
ohort (8418/9479).
ortality rates and SMRs by era of follow-up
Cause-speciﬁc SMR  estimates are presented in Table 2. Causes
f death with SMRs greater than ﬁve in both eras were shortlisted
s major causes, namely DRD, homicide and infectious diseases.
uicide and digestive system diseases were also included as they
ere the second and third most frequent causes of death after DRD
269 and 168 respectively).
The  SDMD cohort’s DRD rates were 498 (95% CI: 454–545) and
57 (95% CI: 334–381) per 100,000 pys in ﬁrst and second era. Sui-
ide was the next most frequent cause of death and, as for DRDs,
e observed a dramatic reduction in rate between eras: 116 (95%
I: 95–140) and 62 (95% CI: 53–73) per 100,000 pys respectively.
Unexpectedly, there was no difference in suicide rate by opiate
isuse declaration (nor, indeed, in homicide rate: data not shown).
n contrast, after controlling for era, DRD rate was  about 30% lower
or clients who  did not declare misuse of opiates at baseline. For
xample, in 1996/97–2000/01, opiate misusers experienced a DRD
ate of 545 (95% CI: 489–604) per 100,000 pys compared with 394
95% CI: 325–472) amongst non-opiate misusers.
The rate of digestive system death increased from 22 (95% CI:
4–34) to 57 (95% CI: 48–67) per 100,000 pys between the ﬁrst and
econd era, respectively. Moreover, the death-rate from digestiveal of Drug Policy 23 (2012) 24– 32 27
diseases  was  higher for clients who  did not declare opiate misuse
at baseline registration compared to those who did: 77 (95% CI:
60–99) versus 48 (95% CI: 38–59) per 100,000 pys in the second
era, respectively.
In  both eras, SMR  was around two  for the remaining (non-major)
causes of death (based on 119 and 443 deaths in ﬁrst and second
era). Nonetheless, SDMD clients’ death-rate from non-major causes
increased between eras: from 127 (95% CI: 105–151) to 173 (95%
CI: 157–190) per 100,000 pys. In both eras, death-rate from non-
major causes was  higher for clients who did not declare misuse of
opiates at baseline registration: 239 (95% CI: 206–275) versus 142
(95% CI: 125–161) per 100,000 pys in the second era. However, for
each era, Table 2 shows that the overall death-rate was  no different
between SDMD clients who did or did not declare misuse of opiates
at baseline.
Proportional hazards analysis: risk factors for drug-related death
SDMD  cohort, and sub-cohorts deﬁned by declared opiate mis-
use at ﬁrst registration: Table 3 analyses risk factors for time to DRD
for the whole SDMD cohort and for the sub-populations who did or
did not report the misuse of opiates at ﬁrst registration.
Younger age was  associated with reduced hazard only amongst
the opiate-declared: HR for ≤34 year olds, 0.75 (95% CI: 0.65–0.86)
versus 1.04 (95% CI: 0.81–1.33) for non-opiate individuals. The
decrease in hazard for females was less dramatic for non-opiate
individuals: HR 0.75 (95% CI: 0.59–0.96) versus 0.53 (95% CI:
0.45–0.62) for the opiate-declared. Time closer to SDMD regis-
tration remained risky for non-opiate individuals (HR for ≤12
weeks versus 1–2 years since registration, 1.59, 95% CI: 1.07–2.36),
as did: present injecting (HR, versus injecting in the past, 1.97,
95% CI: 1.44–2.70), declared alcohol misuse (HR 1.61, 95% CI:
1.22–2.12) and HCV diagnosis (HR for no HCV diagnosis, 0.41, 95%
CI: 0.31–0.54).
DRD-interaction of HCV diagnosis by current age-group
HCV diagnosis had a dramatic inﬂuence on the risk of DRD across
the whole SDMD cohort (HR for no HCV diagnosis, 0.46 with 95%
CI: 0.41–0.53). Ongoing controversy about how age affects DRD risk
could be explained by injectors’ HCV status. On testing, a signiﬁ-
cant interaction was observed between current age-group and HCV
diagnosis which suggested that any age effect on DRD risk applied
to HCV-diagnosed individuals only (21 = 7.7, p = 0.01). Regression
effects (95% CI) were as follows: current age-group ≤ 34 years (vs
>34 years), HR 0.65 (0.52–0.80); no HCV diagnosis (vs HCV diag-
nosed), HR 0.37 (0.30–0.45); and interaction term for ≤34 years
and no HCV diagnosis, HR of 1.44 (1.11–1.85).
Two other interactions for DRD risk were explored between:
(i) sex and HCV diagnosis – only marginally signiﬁcant (21 = 3.2,
p = 0.08); and (ii) injector status and time since most recent registra-
tion – also unremarkable even when only interactions for present
injector were included (24 = 7.9, p = 0.09).
Proportional hazards analysis for other major causes of death –
suicides, homicides, infectious disease or digestive system disease
In  Table 4, for the whole SDMD cohort, we analyse simpliﬁed
risk factors for the other four major causes of death; and, for com-
pleteness, for all non-major causes.
Demographic: Females were at considerably lower risk of sui-
cide and homicide than male counterparts with HRs 0.43 (95% CI:
0.31–0.60) and 0.31 (95% CI: 0.18–0.54) respectively, but current
age-group did not inﬂuence the hazard for suicide or homicide. By
contrast, for deaths from infectious or digestive diseases, the age
28
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Table 2
Observed and expected number of deaths, SMRs and mortality rates in SDMD cohort, Scotland, 1996–2006.a
Cause of death 1996/97–2000/01 (94,040 person-years) 2001/02–2005/06 (256,275 person-years)
Observed Expected SMR  (95% CI) Observed mortality
rateb (95% CI)
Observed Expected SMR (95% CI) Observed mortality
rateb (95% CI)
Drug-relatedc 468 24.0 19.5 (17.8–21.3) 498 (454–545) 915 67.9 13.5 (12.6–14.4) 357 (334–381)
Opiate  misuse at baseline 353 17.1 20.6 (18.5 –22.9) 545 (489–604) 693 48.2 14.4 (13.3–15.5) 396 (367–427)
No  opiate use at baseline 115 6.9 16.7 (13.8–20.0) 394 (325–472) 222 19.7 11.3 (9.8–12.9) 273 (238–311)
Suicidec 109 19.8 5.5 (4.5–6.6) 116 (95–140) 160 43.7 3.7 (3.1–4.3) 62 (53–73)
Opiate  misuse at baseline 78 14.0 5.6 (4.4–7.0) 120 (95–150) 108 30.4 3.6 (2.9–4.3) 62 (51–75)
No  opiate use at baseline 31 5.8 5.3 (3.6–7.6) 106 (72–151) 52 13.3 3.9 (2.9–5.1) 64 (48–84)
Homicidec 32 4.0 8.0 (5.5–11.3) 34 (23–48) 86 10.8 8.0 (6.4–9.9) 34 (27–41)
Infectious  diseasesc 28 2.1 13.1 (8.7–19.0) 30 (20–43) 62 6.6 9.5 (7.3–12.1) 24 (19–31)
Digestive  systemc 21 6.6 3.2 (2.0–4.9) 22 (14–34) 147 32.4 4.5 (3.8–5.3) 57 (48–67)
Opiate  misuse at baseline 9 4.0 2.3 (1.0–4.3) 14 (6–26) 84 19.9 4.2 (3.4–5.2) 48 (38–59)
No  opiate use at baseline 12 2.6 4.6 (2.4–8.0) 41 (21–72) 63 12.6 5.0 (3.9–6.4) 77 (60–99)
All  5 major causes 658 56.5 11.6 (10.8–12.6) 700 (647–755) 1370 161.4 8.5 (8.0–9.0) 535 (506–564)
Opiate  misuse at baseline 476 39.3 12.1 (11.1–13.3) 734 (670–803) 981 110.2 8.9 (8.4–9.5) 561 (526–597)
No  opiate use at baseline 182 17.2 10.6 (9.1–12.2) 623 (536–720) 389 51.2 7.6 (6.9–8.4) 478 (432–528)
Non-major
Circulatory  systemd 22 13.4 1.6 (1.0–2.5) 23 (15–35) 105 53.3 2.0 (1.6–2.4) 41 (34–50)
Accidentald 35 16.9 2.1 (1.4–2.9) 37 (26–52) 65 40.2 1.6 (1.2–2.1) 25 (20–32)
Cancerd 10 13.8 0.7 (0.3–1.3) 11 (5–20) 60 55.6 1.1 (0.8–1.4) 23 (18–30)
Respiratory  systemd 14 3.6 3.9 (2.1–6.5) 15 (8–25) 55 11.4 4.8 (3.6–6.3) 21 (16–28)
Mental  and behaviourald 15 3.1 4.9 (2.7–8.0) 16 (9–26) 44 11.3 3.9 (2.8–5.2) 17 (12–23)
Endocrine  systemd 1 1.8 0.5 (0.0–3.0) 1 (0–6) 17 6.9 2.5 (1.4–3.9) 7 (4–11)
Nervous  systemd 3 4.4 0.7 (0.1–2.0) 3 (1–9) 13 13.2 1.0 (0.5–1.7) 5 (3–9)
All  non-major causes 119 64.5 1.8 (1.5–2.2) 127 (105–151) 443 216.9 2.0 (1.9–2.2) 173 (157–190)
Opiate  misuse at baseline 66 39.7 1.7 (1.3–2.1) 102 (79–130) 249 130.3 1.9 (1.7–2.2) 142 (125–161)
No  opiate use at baseline 53 24.8 2.1 (1.6–2.8) 181 (136–237) 194 86.6 2.2 (1.9–2.6) 239 (206–275)
All  causes 777 121.0 6.4 (6.0–6.9) 826 (769–886) 1813 378.2 4.8 (4.6–5.0) 707 (675–741)
All  except drug-related 309 97.0 3.2 (2.8–3.6) 329 (293–367) 898 310.3 2.9 (2.7–3.1) 350 (328–374)
a Sub-cohort of clients declaring opiate misuse at baseline = 25,674 clients, 542 deaths and 64,817 pys in 1996/97–2000/01 (era 1); and 44,835 clients (25,674 + 19,703 − 542), 1230 deaths, 174,954 pys in 2001/02–2005/06
(era  2). Clients not declaring opiate misuse at baseline = 11,001 clients, 235 deaths and 29,223 pys in era 1; and 23,844 clients (13,078 + 11,001 −235), 583 deaths and 81,322 pys in era 2.
b Per 100,000 person-years
c Drug-related: (F11–F16, F19, X40–X44, X60–X64, X85, Y10–Y14), (304, 305.2–305.9, E850–E858, E950.0–E950.5, E962.0, E980.0–E980.5); suicide: (X65–X84), (E950.6–E959); homicide: (X86–Y09), (E960–E969 excl E962.0);
infectious  diseases: (A00–B99), (001–139); digestive system: (K00–K93), (520–579).
d Circulatory system: (I00–I99), (390–459); accidental: (V01–X59), (E800–E949 excl E850–E858); cancer: (C00–C97), (140–208); respiratory system: (J00–J99), (460–519); mental and behavioural: (F00–F99 excl F11–F16, F19),
(290–319 excl 305.2–305.9); endocrine system: (E00–E89), (240–279); nervous system: (G00–G99), (320–389).
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Table 3
Proportional hazards analysis for DRDs: SDMD cohort and by opiate misuse status at ﬁrst observed SDMD registration (exact p-values cited if less extreme than 0.01).
Whole study population Opiate use at baseline No opiate use at baseline
Multifactorial HR (95% CI)
Current age p = 0.77
≤34 years 0.82 (0.73–0.93) 0.75 (0.65–0.86) 1.04 (0.81–1.33)
>34  years 1.00 1.00 1.00
Sex p = 0.02
Male 1.00 1.00 1.00
Female  0.58 (0.51–0.67) 0.53 (0.45–0.62) 0.75 (0.59–0.96)
Injector  status
Present  injector 1.34 (1.16–1.54) 1.23 (1.04–1.44) 1.97 (1.44–2.70)
Past  injector 1.00 1.00 1.00
Never injector 0.63 (0.53–0.75) 0.66 (0.53–0.82) 0.64 (0.47–0.86)
Unavailable 0.97 (0.74–1.26) 1.13 (0.81–1.58) 0.85 (0.54–1.32)
Health  board of treatment
Lothian 0.87 (0.67–1.12) 0.73 (0.53–1.01) 1.19 (0.79–1.81)
Non-Lothian  1.00 1.00 1.00
Epoch-speciﬁc effect p = 0.03 p = 0.13 p = 0.14
Lothian: 96/97-00/01a 1.52 (1.07–2.16) 1.57 (0.99–2.48) 1.48 (0.83–2.65)
Lothian:  00/01b-02/03 1.01 (0.69–1.46) 1.06 (0.66, 1.73) 0.82 (0.45–1.50)
Drug-treatment  agency p = 0.17 p = 0.87 p = 0.01
GP 0.94 (0.79–1.12) 0.99 (0.81–1.20) 0.83 (0.59–1.19)
Specialist  drug service 1.00 1.00 1.00
Other 1.14 (0.98, 1.34) 1.05 (0.87–1.26) 1.58 (1.14–2.21)
Time  since most recent registration
≤12 weeks 1.32 (1.10–1.59) 1.25 (1.02–1.54) 1.59 (1.07–2.36)
3–12  months 1.12 (0.97–1.30) 1.06 (0.90–1.25) 1.35 (0.98–1.86)
1–2  years 1.00 1.00 1.00
>2–5  years 0.75 (0.65–0.87) 0.69 (0.58–0.81) 1.02 (0.74–1.39)
>5  years 0.39 (0.30–0.50) 0.38 (0.29–0.52) 0.41 (0.25–0.69)
Misuse  of sedatives p = 0.32 p = 0.77 p = 0.02
Yes 1.06 (0.95–1.18) 0.98 (0.86–1.12) 1.33 (1.05–1.69)
No  1.00 1.00 1.00
Misuse  of stimulants p = 0.76 p  = 1.00 p  = 0.48
Yes 1.02 (0.88–1.19) 1.00 (0.82–1.22) 1.10 (0.85–1.43)
No 1.00 1.00 1.00
Misuse  of cannabis or tobacco p = 0.02 p = 0.08
Yes 0.82 (0.72–0.93) 0.84 (0.72–0.98) 0.80 (0.63–1.03)
No  1.00 1.00 1.00
Misuse  of alcohol
Yes 1.76 (1.50–2.06) 1.92 (1.58–2.33) 1.61 (1.22–2.12)
No  1.00 1.00 1.00
HCV  diagnosis
Yes  1.00 1.00 1.00
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Log-likelihood  −14247.25 
ffect was striking with four times greater HR for those aged > 34
ears than for 25–34 year olds.
Drug misuse behaviours: Injector status did not inﬂuence HR
or suicide or for homicide. Past injectors were, as expected, most
t risk of death from infectious disease (HR for present vs. past
njectors 0.41, 95% CI: 0.24–0.69, and for never vs. past injec-
ors, 0.23, 95% CI: 0.10–0.55). Higher risk of death from digestive
ystem disease was evident for SDMD clients who  reported that
hey had never injected: HR 1.52 (95% CI: 0.98–2.34, vs. past
njectors).
There was no compelling effect by drug-treatment agency but
Rs for suicide and homicide decreased as time since most recent
DMD registration elapsed.
Declared alcohol misuse was a major risk factor for death by
uicide (HR 1.88, 95% CI: 1.35–2.60) and especially from digestive
iseases (HR 3.19, 95% CI: 2.21–4.60). Clients who  declared misuse
f cannabis or tobacco had reduced risk of homicide and death from
igestive diseases (respective HRs 0.48, 95% CI: 0.29–0.78, and 0.60,
5% CI: 0.41–0.90), whereas declared misuse of stimulants nearly
oubled suicide risk (HR 1.91, 95% CI: 1.43–2.54).
HCV diagnosis: As for DRDs, HCV diagnosis was associated with
ncreased risks of suicide, homicide and death from digestive sys-
em disease. Individuals without HCV diagnoses were at 50% lower
isk of suicide (HR 0.50, 95% CI: 0.36–0.68); 47% lower risk of0.49 (0.42–0.56) 0.41 (0.31–0.54)
−10411.48 −3039.48
homicide  (HR 0.53, 95% CI: 0.33–0.85); 92% lower risk of infectious-
disease death (HR 0.08, 95% CI: 0.05–0.13); and 85% lower risk of
digestive-system-related death (HR 0.15, 95% CI: 0.10–0.22).
Discussion
We  have presented a detailed study of the cause-speciﬁc mor-
tality of individuals in contact with Scotland’s drug-treatment
services. The top causes of death were: drug-related, homicide and
infectious diseases (based on SMR  > 5); or suicide and digestive sys-
tem disease (as second and third most frequent cause of death).
Together, these major causes accounted for 2028 (78%) of the 2590
deaths.
SDMD clients’ DRD and suicide rates fell equally dramatically
between eras. These important decreases may be explained by
improvement in drug-treatment and other services, including for
suicide prevention. We  cannot, however, exclude that expansion of
drug treatment services may  have made them available to a broader
range of SDMD clients. Not all problem drug-users access treatment
and Scotland’s DRDs steadily increased from 244 in 1996 to 421 in
2006 (GROS, 2009).
For  individuals diagnosed with HCV, higher hazards for each
major cause (and all non-major causes) were a striking feature
– with the most extreme HRs for infectious or digestive disease
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Table  4
Proportional hazards analysis for other major causes of death: cause-speciﬁc mortality (exact p-values cited if less extreme than 0.01).
Suicide Homicide Infectious-diseases Digestive-system Non-major causes
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Current age p = 0.93 p = 0.29 Current age
≤34  years 0.99  (0.74–1.32) 0.80 (0.53–1.20) <25 years 0.15 (0.05–0.42) 0.05 (0.02–0.15) 0.24 (0.19–0.32)
>34  years 1.00 1.00 25–34 years 0.25 (0.15–0.41) 0.24 (0.17–0.35) 0.28 (0.23–0.34)
>34  years 1.00 1.00 1.00
Sex  Sex p = 0.80 p = 0.12
Male  1.00 1.00 Male 1.00 1.00 1.00
Female 0.43  (0.31–0.60) 0.31 (0.18–0.54) Female 0.94 (0.59–1.50) 0.76 (0.53–1.08) 0.70 (0.57–0.85)
Injector  status p = 0.35 p = 0.33 Injector status p = 0.01
Known  ever injector 1.00 1.00 Present injector 0.41 (0.24–0.69) 0.72 (0.48–1.08) 0.95 (0.74–1.22)
Not  known ever injected 0.88 (0.67–1.15) 1.23 (0.82–1.84) Past injector 1.00 1.00 1.00
Never injector 0.23 (0.10–0.55) 1.52 (0.98–2.34) 1.57 (1.23–2.00)
Unavailable 0.80 (0.36–1.77) 0.97 (0.49–1.92) 1.57 (1.10–2.23)
Health  board p = 0.79 Health  board p = 0.77 p = 0.02
Argyll and Clyde 1.00 2.45 (1.24–4.82)
Lothian 0.95 (0.68–1.34) 1.00 Lothian 2.50 (1.55–4.02) 1.06 (0.70–1.61) 0.76 (0.60–0.97)
Greater  Glasgow 1.00 1.90 (1.02–3.55) Non-Lothian 1.00 1.00 1.00
Elsewhere 1.00 1.05  (0.55–1.99)
Drug tx. agency p = 0.09 p = 0.75 Drug tx. agency p = 0.49 p = 0.12 p = 0.29
GP 0.66 (0.42–1.02) 0.82 (0.45–1.51) GP 1.06 (0.62–1.80) 0.81 (0.49–1.34) 1.23 (0.96–1.58)
Specialist  service 1.00 1.00 Specialist service 1.00 1.00 1.00
Other  0.79 (0.51–1.22) 0.85 (0.43–1.66) Other 0.61 (0.24–1.52) 0.52 (0.25–1.08) 1.04 (0.76–1.41)
Time  since most recent registration p = 0.01 p = 0.01 p  = 0.79 p = 0.05
≤12  months 1.17 (0.86–1.60) 1.20 (0.74–1.94) 0.81 (0.45–1.45) 0.95 (0.63–1.44) 1.00 (0.79–1.27)
1–2  years 1.00 1.00  1.00 1.00 1.00
2–5  years 0.87 (0.62–1.22) 0.90 (0.54–1.48) 0.82 (0.47–1.46) 0.62 (0.41–0.95) 0.91 (0.73–1.15)
>5  years 0.49 (0.28–0.86) 0.35 (0.15–0.83) 1.07 (0.51–2.22) 0.62 (0.38–1.01) 0.58 (0.43–0.79)
Misuse  of sedatives p = 0.16 p = 0.14 p = 0.23 p = 0.24 p = 0.31
Yes 0.83 (0.64–1.08) 1.34 (0.92–1.95) 0.73 (0.43–1.23) 0.81 (0.56–1.16) 1.10 (0.92–1.32)
No 1.00 1.00 1.00 1.00  1.00
Misuse  of stimulants p = 0.73 p = 0.32 p = 0.82 p = 0.01
Yes 1.91  (1.43–2.54) 1.10 (0.65–1.84) 0.66 (0.28–1.55) 0.95 (0.60–1.50) 0.70 (0.54–0.92)
No  1.00 1.00 1.00 1.00 1.00
Misuse  of cannabis/tobacco p = 0.10 p = 0.97 p = 0.01 p = 0.08
Yes 0.80 (0.60–1.05) 0.48 (0.29–0.78) 0.99 (0.59–1.67) 0.60 (0.41–0.90) 0.84 (0.68–1.03)
No  1.00 1.00 1.00 1.00 1.00
Misuse  of alcohol p = 0.11 p  = 0.47
Yes  1.88 (1.35–2.60) 1.59 (0.92–2.75) 1.29 (0.66–2.54) 3.19 (2.21–4.60) 1.87 (1.49–2.35)
No 1.00  1.00 1.00 1.00 1.00
HCV  diagnosis p = 0.01
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No  0.50 (0.36–0.68) 0.53 (0.33–0.85) 
Log-likelihood  −2771.21 −1217.48 
eaths which include liver-related causes. McDonald et al. (2009)
eported higher DRD rate and liver-related mortality in those HCV-
iagnosed compared with the general Scottish population. We  ﬁnd
hat, even within the SDMD cohort, HCV-diagnosed individuals
ere particularly vulnerable, and not only to causes of death readily
ssociated with HCV or injecting. The biological ageing associated
ith HCV-shortening of telomeres (Hoare, Das, & Alexander, 2010a;
oare et al., 2010b) may  be a contributory explanation for the dou-
ling in DRD, suicide, and non-major cause risks, but is an unlikely
xplanation for increased homicide risk. In policy terms, HCV diag-
osis appears an important indicator of those needing support to
itigate a range of mortality risks.
The age effect on DRD risk appeared speciﬁc to HCV-diagnosed
ndividuals, consistent with the hypothesis that HCV-related liver
amage enhances the risk of overdose (Darke, Degenhardt, &
attick, 2007). The observed interaction may  explain conﬂicting
vidence on how strongly age inﬂuences DRD risk if there is con-
ounding by HCV diagnosis (Bird, Hutchinson, & Goldberg, 2003;
OSMO Workshop, 2010).
The SDMD cohort was sufﬁciently large to investigate HR inﬂu-
nces on other major causes of death besides DRDs, and for all
on-major causes. Here, we brieﬂy comment on the more major,
r novel ﬁndings.
The  association of stimulant misuse with increased suicide risk
as unexpected and, to our knowledge, has not been demonstrated1.00 1.00 1.00
0.08 (0.05–0.13) 0.15 (0.10–0.22) 0.45 (0.36–0.56)
−787.66 −1654.96 −5833.51
before.  Wilcox, Conner, and Caine (2004) meta-analysed suicide
SMRs in cohorts with speciﬁc drug use and alcohol disorders but
identiﬁed a lack of studies on stimulant misuse, whilst Borges,
Walters, and Kessler (2000) only measured drug misuse associ-
ations with ﬁrst suicide attempt. Reverse causation is a possible
explanation for our ﬁnding, if those with depressive tendency self-
medicated by using stimulants. Suicides may  also result from a
profound ‘crash’ after stimulant-induced euphoria.
Declared alcohol misuse increased the hazards of DRD, suicide,
homicide, digestive-system-disease fatalities, and also of death
from non-major causes. Alcohol is a major cause of liver disease and
commonly detected at fatal heroin overdoses (Darke, Ross, Zador,
& Sunjic, 2000; Davidson et al., 2003; Fugelstad et al., 2003) and is
also well-known for its association with both suicidal and violent
behaviour (Allgulander & Nilsson, 2000; Wilcox et al., 2004).
Stronger  associations between time to DRD and demographic
characteristics were observed for individuals who  declared opi-
ate misuse at ﬁrst registration. However, within 12 weeks after
any SDMD registration was  hazardous for DRDs irrespective of
opiate declaration, or not, at ﬁrst registration; and injector sta-
tus was also as DRD-critical for the self-declared non-opiate
sub-population. Greater DRD hazard for present injectors in the
non-opiate sub-population may  reﬂect a particularly chaotic regis-
tration or unwillingness to declare risk behaviours to the treatment
provider – to the detriment of getting appropriate treatment.
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Other studies (e.g. Bartu, Freeman, Gawthorne, Codde, &
olman, 2004; COSMO Workshop, 2010; Fugelstad, Annell, Rajs,
 Agren, 1997) have not compared initially deﬁned subgroups of
rug-users, perhaps for good reason, as we found similar propor-
ions of the DRDs in each of our two sub-populations referring
o opioids speciﬁcally: 54% (584/1046) and 56% (156/337) in the
nitially declared opiate and non-opiate sub-populations respec-
ively. Of three recent systematic reviews of mortality for users
f speciﬁc drugs (amphetamines, cocaine, or opioids: Degenhardt
t al., 2010, 2011; Singleton, Degenhardt, Hall, & Zabransky, 2009),
nly the one, which concerned regular or dependent users of
eroin and other opioids, was able to draw robust but limited
nferences on all-cause and overdose-related mortality. The evolv-
ng manner of drug use behaviours is better accounted for by
tting time-dependent covariates than by baseline classiﬁcation.
s demonstrated in Table 3, such time-dependent covariates are
till needed in combination with any major initially deﬁned sub-
ohort such as declared misuse of opiates. We  do not place absolute
eliance on SDMD’s elicited drug histories, which others have ques-
ioned also (Casey, Hay, Godfrey, & Parrott, 2009). In particular, our
ndicators do not differentiate serious (dependent) use.
SDMD  records did not indicate dates of transfer or discharge
rom drug-treatment which would have been insightful: see ISD
2008) for later developments. Moreover, those that registered for
rug treatment in the earlier era may  have matured out of their
rug habit by the later era. However, additional SMR  analyses for
001/02 to 2005/06 according to the era of clients’ ﬁrst observed
egistration did not reveal signiﬁcant differences between these
wo cohorts except in respect of deaths from infectious diseases
see Table S1).
Our  analyses were not adjusted for deprivation. To measure
eprivation, postcode of residence was needed and, unfortunately,
as only available for 57% (39,567/69,456) of SDMD clients at ﬁrst
bserved registration, with undocumented changes over follow-
p. Had we taken account of clients’ deprivation quintile, we might
ave observed SMRs that were less extreme but only modestly so:
y about 10% to judge by McDonald et al. (2011).
In addition, deaths, diagnoses, referrals and movements outside
f Scotland were not followed up. Based on Bloor et al. (2008), we
ight expect a further 68 deaths (less than 3%) to have occurred
utside Scotland. Our estimates may  thereby suffer slight attenua-
ion or distortion.
onclusion
We  have been able to investigate ﬁve major causes of death in a
ulnerable sub-population of nearly 70,000 drug treatments clients
ith over 350,000 pys of observation. We  have highlighted reserva-
ions about the probabilistic linkage, recording of drugs of misuse
nd that SMRs may  be slightly exaggerated without adjustment for
eprivation. In terms of prognostication, our ﬁndings have been
enerally consistent with previous studies which gives grounds
or conﬁdence in the new insights that our investigations have
dded: ﬁrstly, that HCV diagnosis marked out drug-user clients at
igher risk of ﬁve major (DRD, suicide, homicide, infectious disease,
igestive system) and all non-major causes of death; secondly, that
eclared stimulant misuse was associated with a higher risk of sui-
ide; and that higher DRD risk at older age may  be speciﬁc for the
CV diagnosed.
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Appendix A. Probabilistic linkage
Records were linked by ISD: there were 413,998 medical records
(hospital admissions, cancer registrations and death records),
146,993 SDMD records and 20,969 HCV diagnoses, corresponding
to 83,154 individuals. Linkages with hospitalisation/death records
were attempted ﬁrst (54,220 individuals: 116,158 SDMD records,
16,840 HCV diagnoses). In the absence of a link with the death
data set, direct links between the SDMD and HCV records were
attempted (370 individuals: 908 SDMD records, 370 HCV diag-
noses). There were 29,927 SDMD records (24,805 individuals)
and 3759 HCV diagnoses (3759 individuals) that failed to link
at all.
Records were linked by a probabilistic process in three key
stages:
1. Short  listing pairs of records to be considered for linkage. ISD
shortlisted  pairs of records that agree on either:
(a) surname soundex (ﬁrst and fourth letter of surname for pairs
including SDMD records), forename initial and sex; or,
(b) day, month and year of birth.
2. Calculating the corresponding linkage score, as described by
Newcombe  (1988):
Frequency  of outcome (x, y) among LINKED pairs
Frequency of outcome (x, y) among UNLINKABLE pairs
For forename initial, ﬁrst and fourth letter of surname, fre-
quencies  (expressed as percentages of the population) were
estimated from the community health index (CHI) for all indi-
viduals  registered with a general practitioner (GP) in Scotland.
For  postcode, GROS data were used. For the other identiﬁers, the
linked data set of all Scottish hospital discharges, cancer regis-
trations  and deaths was  used for the denominator frequencies.
For  each shortlisted record-pair, the frequency ratio of relevant
identiﬁers was calculated and then log-transformed to base 2, to
yield binit weights. The binit weights were then summed to give
an  overall linkage score (LS).
For linkages between SDMD and hospitalisation/death
records, the internal linkages of the hospitalisation/death data
set  were exploited. If the hospital/death record in the shortlisted
record-pair corresponded to an individual who  had had a drug-
related  admission (during 1st January 1980–30 June 2006) then
a  bonus of three points was added to LS above.
3.  Choosing the threshold score for accepting matches.
Of rival matches, the record-pair with the highest linkage score
will be selected for linkage providing that the respective score is
above the threshold. Besides a death record, individuals may  have
multiple hospitalisation records, SDMD registrations and even HCV
diagnoses. Suppose we  compare individual P’s  hospitalisation
records with individual Q’s  SDMD registrations. The LS is calcu-
lated for each of the  combinations of (shortlisted) record-pairs.
If the mean score is both above the threshold score and higher
than any rival matches, then individual P and individual Q will be
assumed to be the same individual.
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